Regorafenib (Belvango) complete instructions and what you need to know before taking it

Regorafenib is an oral multi-target tyrosine kinase inhibitor mainly used for the treatment of advanced colorectal cancer, gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC). Its mechanism of action is by inhibiting angiogenesis-related receptors such as VEGFR1-3, PDGFR, and FGFR, as well as tumor growth and metastasis phases. It can block tumor blood vessel formation, inhibit tumor proliferation and promote tumor cell apoptosis through various signaling pathways including KIT, RET, and RAF. Due to its multi-target properties, regorafenib has shown certain efficacy in the clinical application of a variety of solid tumors.

Before using regorafenib, patients need to fully understand the key information in the drug package insert. First of all, you should clarify the type of your disease and whether your condition is consistent with the indications for regorafenib. Clinically, regorafenib is usually used in patients who have failed or relapsed after standard chemotherapy or targeted therapy. Secondly, patients need to inform their doctors of their past medical history, especially cardiovascular disease, hypertension, bleeding disorders, abnormal liver and kidney function, and gastrointestinal ulcers, which may affect the safety of medication. For pregnant women, lactating women and patients planning pregnancy, use should be avoided and effective contraceptive measures should be taken.

Before taking regorafenib, you need to pay attention to drug interactions. Regorafenib is mainly metabolized by the liver CYP3A4 enzyme, so it should be avoided to be used together with strong CYP3A4 inhibitors or inducers to prevent abnormal increase or decrease in blood concentration. At the same time, when patients use anticoagulants, antiplatelet drugs or other drugs that may increase the risk of bleeding, they should adjust the dosage or monitor relevant indicators under the guidance of a doctor. In addition, regorafenib may affect liver function and blood indicators, so blood routine, liver and kidney function, and blood pressure assessments need to be performed before treatment for dynamic monitoring during treatment.

The instructions for taking regorafenib must also be strictly followed. The drug is usually taken once a day, with or without food, but regular medication time should be maintained to ensure stable blood concentration. The standard treatment course is 21 days of continuous medication followed by 7 days as one cycle. The specific dose needs to be adjusted based on the patient's weight, tolerance and doctor's evaluation. During the medication period, patients should pay close attention to their physical condition. If adverse reactions such as hand-foot syndrome, high blood pressure, rash, fatigue, or digestive tract discomfort occur, they should promptly inform the doctor so that measures such as dose adjustment, symptomatic treatment, or medication suspension can be taken. By strictly abiding by the instructions and doctor's guidance, patients can maximize the efficacy of regorafenib and achieve standardized treatment management while ensuring safety.

Reference link:https://www.drugs.com